AI assistant
NYRADA INC. — Capital/Financing Update 2025
Oct 21, 2025
65469_rns_2025-10-21_a21aeff3-9586-4c13-be1a-1f6b04013803.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [595 x 104] intentionally omitted <==
22 October 2025
Sydney, Australia
Cleansing Statement
Nyrada Inc. (ASX:NYR), a clinical stage drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel inhibitors, today announces the issue of:
- (i) 76,667 CHESS Depositary Interests (CDIs) further to the Appendix 2A lodged today. The CDIs are in respect of options exercised.
NYR gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:
-
1 The CDIs were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
-
2 As at the date of this notice, NYR has complied with:
-
(a) The provisions of Chapter 2M of the Corporations Act as they apply to NYR; and (b) Section 674 and 674A of the Corporations Act.
-
3 As at the date of this notice, there is no information that is “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.
For and on behalf of the Board,
Yours faithfully,
==> picture [105 x 61] intentionally omitted <==
David Franks Company Secretary
-ENDS-
Page 1 ARBN 625 401 818
Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000
==> picture [595 x 104] intentionally omitted <==
About Nyrada Inc.
Nyrada Inc. is a clinical stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company’s lead candidate, Xolatryp[TM] , has shown efficacy in both neuroprotection and cardioprotection, positioning it for a first-inhuman Phase I clinical trial. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.
www.nyrada.com
Authorised by Mr. John Moore, Non-Executive Chair on behalf of the Board.
Investors and Media: Company Secretary: Dimitri Burshtein David Franks T: 02 9498 3390 T: 02 8072 1400 E: [email protected] E: [email protected]
Forward-Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.
Page 2 ARBN 625 401 818
Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000